Characterization of changes in serum anti-glycan antibodies in Crohn's disease--a longitudinal analysis.
Characterization of changes in serum anti-glycan antibodies in Crohn's disease--a longitudinal analysis.
复制标题
DOI：
10.1371/journal.pone.0018172
复制
发表时间：
2011-05-06
期刊：
影响因子：
3.7
通讯作者：
Klebl F
中科院分区：
文献类型：
--
作者：
Rieder F;Lopez R;Franke A;Wolf A;Schleder S;Dirmeier A;Schirbel A;Rosenstiel P;Dotan N;Schreiber S;Rogler G;Klebl F
抗聚糖抗体是克罗恩病（CD）患者鉴别诊断和疾病分层的一种有前途的工具。我们纵向评估了CD患者抗聚糖抗体水平和状态随时间的变化以及这种现象的决定因素。通过ELISA检测来自253名炎症性肠病（IBD）患者（207名CD患者，46名溃疡性结肠炎（UC）患者）的859份血清样品中抗海带多糖（Anti-L）、抗几丁质（Anti-C）、抗壳双糖苷（ACCA）、抗海带双糖苷（ALCA）、抗甘露双糖苷（AMCA）和抗酿酒酵母（gASCA）抗体的存在。所有患者在病程中至少采集2份至11份血清样本。CD的中位随访时间为17.4个月（四分位距（IQR）8.0，31.6个月），UC为10.9个月（IQR 4.9，21.0个月）。在CD受试者的一个亚组中，随着时间的推移，观察到总体免疫反应（四分位数总和评分）和个体标志物水平的显着变化。标志物状态（阳性与阴性）保持广泛稳定。临床表型和NOD 2基因型均与观察到的波动无关。在纵向分析中，疾病活动性和CD行为的变化均未导致聚糖标志物水平的改变。该小组区分CD与UC的能力或其与CD表型的相关性在随访期间保持稳定。在UC患者的血清中，未观察到显著水平或状态变化。虽然抗聚糖抗体水平在CD患者亚组中波动，但抗体状态随时间广泛稳定。
Anti-glycan antibodies are a promising tool for differential diagnosis and disease stratification of patients with Crohn's disease (CD). We longitudinally assessed level and status changes of anti-glycan antibodies over time in individual CD patients as well as determinants of this phenomenon. 859 serum samples derived from a cohort of 253 inflammatory bowel disease (IBD) patients (207 CD, 46 ulcerative colitis (UC)) were tested for the presence of anti-laminarin (Anti-L), anti-chitin (Anti-C), anti-chitobioside (ACCA), anti-laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-Saccharomyces cerevisiae (gASCA) antibodies by ELISA. All patients had at least two and up to eleven serum samples taken during the disease course. Median follow-up time for CD was 17.4 months (Interquartile range (IQR) 8.0, 31.6 months) and for UC 10.9 months (IQR 4.9, 21.0 months). In a subgroup of CD subjects marked changes in the overall immune response (quartile sum score) and levels of individual markers were observed over time. The marker status (positive versus negative) remained widely stable. Neither clinical phenotype nor NOD2 genotype was associated with the observed fluctuations. In a longitudinal analysis neither changes in disease activity nor CD behavior led to alterations in the levels of the glycan markers. The ability of the panel to discriminate CD from UC or its association with CD phenotypes remained stable during follow-up. In the serum of UC patients neither significant level nor status changes were observed. While the levels of anti-glycan antibodies fluctuate in a subgroup of CD patients the antibody status is widely stable over time.
登录
查看更多内容
DOI：
10.1016/j.cgh.2008.04.032
发表时间：
2008-10
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
Dubinsky MC;Kugathasan S;Mei L;Picornell Y;Nebel J;Wrobel I;Quiros A;Silber G;Wahbeh G;Katzir L;Vasiliauskas E;Bahar R;Otley A;Mack D;Evans J;Rosh J;Hemker MO;Leleiko N;Crandall W;Langton C;Landers C;Taylor KD;Targan SR;Rotter JI;Markowitz J;Hyams J;Western Regional Pediatric IBD Research Alliance;Pediatric IBD Collaborative Research Group;Wisconsin Pediatric IBD Alliance
通讯作者：
Wisconsin Pediatric IBD Alliance
影响因子：
2.6
作者：
Dotan, N.;Altstock, R. T.;Dukler, A.
通讯作者：
Dukler, A.
影响因子：
29.4
作者：
Landers, CJ;Cohavy, O;Targan, SR
通讯作者：
Targan, SR
DOI：
10.1046/j.1440-1746.2000.02357.x
发表时间：
2000-12-01
影响因子：
4.1
作者：
Oshitani, N;Hato, F;Kuroki, T
通讯作者：
Kuroki, T
影响因子：
29.4
作者：
FARMER, RG;WHELAN, G;FAZIO, VW
通讯作者：
FAZIO, VW